Rosuvastatin induced pruritus and dizziness: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242953Keywords:
Rosuvastatin, Statins, Pruritus, Dizziness, Adverse effectsAbstract
Drug-associated adverse reactions can manifest with a wide range of symptoms. Some are widely reported, while others are less commonly observed. This case report describes a 36-year-old woman who was prescribed rosuvastatin to manage her elevated triglyceride levels and experienced adverse effects like pruritus and dizziness within ten days of starting the medication. After discontinuing rosuvastatin, her dizziness resolved immediately, and the pruritus diminished over the following two weeks, eventually subsiding completely. This case underscores the importance of considering Rosuvastatin-related adverse effects when evaluating patients with similar complaints.
References
Song J, Xian D, Yang L, Xiong X, Lai R, Zhong J. Pruritus: progress toward pathogenesis and treatment. Biomed Res Int. 2018;2018:9625936.
Post RE, Dickerson LM. Dizziness: a diagnostic approach. Am Fam Physician. 2010;82:361-8.
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:81.
Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs. 2010;10:11-28.Khan FS, Stewart DK, Brunzell JD, Natrajan KM, Castells MC, Henderson WR Jr, et al. Successful desensitization to rosuvastatin in a patient with a history of anaphylaxis to multiple statins. J Allergy Clin Immunol. 2013;131:234-6.
Schultz AE, Snider MJ, Blais DM, Gulati M. Statin desensitization in a patient with probable familial hypercholesterolemia. J Clin Lipidol. 2015;9:597-601.
Kim W, Yoon YE, Shin SH, Bae JW, Hong BK, Hong SJ, et al. Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Clin Ther. 2018;40(6):993-1013.
Oh GC, Han JK, Han KH, Hyon MS, Doh JH, Kim MH, et al. Efficacy and safety of fixed-dose combination therapy with telmisartan and rosuvastatin in Korean patients with hypertension and dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a multicenter, randomized, 4-arm, double-blind, placebo-controlled, phase III study. Clin Ther. 2018;40:676-91.
Zhang R, Li Y, Jiang X, Wang L. Pharmacokinetics and tolerability of multiple-dose rosuvastatin: an open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers. Curr Ther Res Clin Exp. 2009;70:392-404.
Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med. 2010;25:27-35.
Lee J, Rhee SJ, Lee S, Yu KS. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians. Drug Des Devel Ther. 2018;12:787-94.
Roh H, Son H, Lee D, Chang H, Yun C, Park K. Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Clin Ther. 2014;36:1159-70.
Kim H, Kim N, Lee DH, Kim HS. Analysis of national pharmacovigilance data associated with statin use in Korea. Basic Clin Pharmacol Toxicol. 2017;121:409-13.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
Malik S, Cohen PR. Rosuvastatin-Induced Dizziness and Pruritus: A Case Report and Summary of Statin-Associated Dizziness and Pruritus. Cureus. 2022;14(9):e29014.
